Stockholders' Equity (Details Textual) - USD ($)		1 Months Ended			12 Months Ended
	Nov. 09, 2017	Nov. 26, 2019	Aug. 14, 2019	Mar. 09, 2018	Dec. 31, 2019	Dec. 31, 2018	Jun. 13, 2016	Jan. 19, 2016
Stockholders' Equity (Textual)
Stock-based compensation for stock options issued					$ 2,242,000	$ 1,018,000
Unrecognized compensation expense					$ 1,856,000
Weighted average remaining contractual life					1 year 7 months 6 days
Aggregate principal					$ 7,500,000
Warrant purchase					90,000
Debt discount					$ 313,097
Sale of common stock					1,768,012
Total sale value					$ 15,200,000
New ATM agreement, description					The Company has approximately $2.1 million available under its current ATM program and $30.3 million available under its current shelf registration for the issuance of equity, debt or equity-linked securities unrelated to the current ATM program.
Warrants issued, description					The Company amended and restated the following warrants held by Elliott and its affiliates to reduce the exercise price of each warrant to $0.005 per share: warrants issued in May 2013 to purchase up to an aggregate of 100,000 shares of the Company's common stock with a pre-amendment exercise price of $3.25 per share and an expiration date of May 30, 2019, which was subsequently extended to August 16, 2019 (the "May 30, 2019 Warrants"), (see Note 4); and warrants issued in October 2013 to purchase up to an aggregate of 150,000 shares of the Company's common stock with a pre-amendment exercise price of $4.50 per share and an expiration date of October 22, 2019 (the "October 22, 2019 Warrants").
Preferred stock, par value					$ 0.001	$ 0.001
Preferred stock, shares authorized					2,000,000	2,000,000
Securities purchase agreement, description	The Company entered into a securities purchase agreement which, on November 16, 2017, resulted in the Company selling $2.0 million of its Series F preferred stock ("Series F Stock") at $1,000 per share. Based on the terms of the Series F Stock, the conversion price was $0.81. The conversion price of the Series F Stock was subject to anti-dilution adjustment for customary recapitalization events such as stock splits, as well as full ratchet anti-dilution protection in the event that the Company did not obtain the subordination of the Series C-3 preferred stock to that of the Series F Stock or obtain stockholder approval, if required by NYSE American rules, of the issuance of common stock that exceeds NYSE American rules. All outstanding shares of Series F Stock were cancelled in connection with the terms of the Exchange Agreement, as described below.
Dividend yield					0.00%
Expected term, description					To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of the Company’s awards which is 5 years for employees and 10 years for non-employees.
Deferred compensation					$ 36,500	$ 30,000
StockOptionMember
Stockholders' Equity (Textual)
Intrinsic value of stock options exercised					$ 154,589	42,400
2013 Stock Incentive Plan [Member]
Stockholders' Equity (Textual)
Conversion of stock, description					The Company granted ten-year qualified and non-qualified stock options to its officers, directors, employees and consultants covering an aggregate of 496,300 shares of the Company’s common stock under the 2013 Plan. The weighted average exercise price of these options is $7.64 per share.
Common stock reserved for issuance					1,000,000
2013 Stock Incentive Plan [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Increase common stock issuable							1,600,000	1,000,000
2013 Stock Incentive Plan [Member] | Minimum [Member]
Stockholders' Equity (Textual)
Increase common stock issuable							2,200,000	1,600,000
2019 Omnibus Stock Incentive Plan [Member]
Stockholders' Equity (Textual)
Remaining common stock issuance, description		The Company's shareholders approved the CorMedix Inc. 2019 Omnibus Stock Incentive Plan (the "2019 Plan"). Pursuant to the 2019 Plan and subject to certain adjustments as described below, the Company may issue up to 3,000,000 shares of its common stock, plus any shares that remain available for grant under its 2013 Plan as of the effective date (up to a maximum carry-forward of 522,606 shares plus any outstanding options under the 2013 Plan that were canceled, forfeited and expired after the approval of the 2019 Plan), as long-term equity incentives to the Company's employees, consultants, and directors.
Series C-2 Preferred Stock [Member]
Stockholders' Equity (Textual)
Exchange agreement, description					Pursuant to the terms of the Exchange Agreement, the exchange of the Series C-2 preferred stock, Series D preferred stock, Series F preferred stock and the 10% senior secured convertible note was considered an extinguishment. As a result, the difference between the fair value allocated to the Series G preferred stock and the carrying value of the Series C-2 preferred stock, Series D preferred stock, Series F preferred stock and the 10% senior secured convertible note is being treated as a deemed dividend and is added to net loss to arrive at loss available to common stockholders.
Series G Voting Convertible Preferred Stock [Member]
Stockholders' Equity (Textual)
Preferred stock conversion price per share					$ 7.93
Conversion of stock, description					Each share of Series G preferred stock is convertible into approximately 55.5978 shares of our common stock (subject to adjustment as provided in the certificate of designation for the Series G preferred stock) at a per share price of $3.37 at any time at the option of the holder, except that a holder will be prohibited from converting shares of Series G preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 4.99% of the total number of shares of our common stock then issued and outstanding.
Proceeds from issuance of preferred stock					$ 187.36452
Debt restriction, description					As long as any of the Series G preferred stock is outstanding, we cannot create, incur, guarantee, assume or suffer to exist any indebtedness, other than (i) trade payables incurred in the ordinary course of business consistent with past practice, and (ii) up to $10 million aggregate principal amount of indebtedness with a maturity less than twelve months outstanding at any time, which amount may include up to $5 million of letters of credit outstanding at any time.
Exchange agreement, description					These fair values, along with the fair value of the 10% senior secured convertible note were utilized to allocate the fair value of the Series G preferred stock based on relative fair values.
Senior Secured Convertible Note [Member]
Stockholders' Equity (Textual)
Warrant purchase					90,000
Exchange agreement, description					The Exchange Agreement, the Company recognized a deemed dividend of $26,733,098. The deemed dividend was comprised of (1) a beneficial conversion related to the 10% secured senior convertible note recognized at extinguishment; (2) the difference between the allocated fair value of the Series G Preferred Stock issued and the carrying values of the 10% secured senior convertible note, the Series C-2 Preferred Stock, Series D Preferred Stock and Series F Preferred Stock; (3) the difference between the fair value of the exchanged warrants before and after the Exchange Agreement; and (4) the difference between the fair value and the carrying value of Series E Preferred Stock, less the fair value of the Series E warrants that were cancelled as part of the Exchange Agreement.
Expected term, description					The Exchange Agreement, the senior secured convertible note, along with certain warrants and the Series C-2, Series D and Series F preferred stock, and the payment of $2,000,000, was exchanged for 100,000 shares of Series G preferred stock. As a result of this transaction, the Company recognized a deemed dividend of $26,733,098 on its condensed consolidated statement of operations and comprehensive loss for the year ended December 31, 2019 (see Note 8).
Series C-3 Non-Voting Preferred Stock [Member]
Stockholders' Equity (Textual)
Non-voting preferred stock, description					The Company issued 104,000 shares of its common stock upon conversion of 52,000 shares of Series C-3 non-voting preferred stock.
Conversion of stock, description					Each share of Series C-3 preferred stock is convertible into 2 shares of our common stock (subject to adjustment in the event of stock dividends and distributions, stock splits, stock combinations, or reclassifications affecting our common stock) at a per share price of $5.00 at any time at the option of the holder, except that a holder will be prohibited from converting shares of Series C-3 preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of our common stock then issued and outstanding.
Proceeds from issuance of preferred stock					$ 10
Series E non-voting convertible preferred stock
Stockholders' Equity (Textual)
Preferred stock conversion price per share					$ 7.93
Conversion of stock, description					Each share of Series E preferred stock is convertible into 4.3733 shares of our common stock (subject to adjustment as provided in the certificates of designation for the Series E preferred stock) at a per share price of $3.75 at any time at the option of the holder, except that a holder will be prohibited from converting shares of Series E preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 4.99% of the total number of shares of our common stock then issued and outstanding.
Proceeds from issuance of preferred stock					$ 49.20
Debt restriction, description					As long as any of the Series E preferred stock is outstanding, we cannot create, incur, guarantee, assume or suffer to exist any indebtedness, other than (i) trade payables incurred in the ordinary course of business consistent with past practice, and (ii) up to $10 million aggregate principal amount of indebtedness with a maturity less than twelve months outstanding at any time, which amount may include up to $5 million of letters of credit outstanding at any time.
Exchange agreement [Member]
Stockholders' Equity (Textual)
Exchange agreement, description			The Company entered into the Exchange Agreement with Elliott, pursuant to which Elliott agreed to exchange all of its outstanding warrants, its 10% senior secured convertible note and its shares of Series C-2 preferred stock, Series D preferred stock and Series F preferred stock, and make a cash payment of $2.0 million to the Company, for 100,000 shares of Series G preferred stock, with an aggregate liquidation preference of $18,736,452, which are convertible into an aggregate of 5,560,138 shares of the Company’s common stock at a conversion price of $3.37 per share. Elliott retained the shares of the Company’s common stock and Series E preferred stock that it held at the time of the consummation of the Exchange Agreement. Other than with respect to conversion price and liquidation preference, the Series G preferred stock has substantially the same terms as the Company’s outstanding Series E preferred stock, including the restrictive covenants contained therein as modified as set forth in the Exchange Agreement. However, Elliott is prohibited from converting the Series G preferred stock into shares of the Company’s common stock to the extent that, as a result of such conversion, Elliott would own more than 4.99% of the total number of shares of the Company’s common stock then issued and outstanding. The shares of Series G preferred stock are entitled to vote on an as-converted basis with respect to the number of shares of common stock into which they are convertible, based upon an assumed conversion price, solely for the purpose of the voting rights, equal to $7.93, the closing price of the Company’s common stock on August 14, 2019, and the Series E preferred stock was modified to provide for similar rights to vote on an as-converted basis. The Company filed the Certificate of Designation of the Series G preferred stock and the Second Amended and Restated Certificate of Designation of the Series E preferred stock with the Secretary of State of the State of Delaware on September 5, 2019. On September 6, 2019, the Company closed this transaction and issued the Series G preferred stock.
Restricted Stock Unit
Stockholders' Equity (Textual)
Stock issued for restricted stock units vested					25,346
Compensation expense					$ 198,000	93,000
Unrecognized compensation expense					$ 11,000	$ 23,000
Weighted average remaining contractual life					2 months 8 days
Restricted stock units issued					24,850	18,900
Restricted stock units forfeited					2,830
Restricted stock units outstanding					2,490
Weighted average grant date fair value					$ 8.33	$ 3.50
Common Stock [Member]
Stockholders' Equity (Textual)
New ATM agreement, description				The Company had a prior sales agreement with B. Riley for its ATM program, which expired on April 16, 2018, under which the Company could issue and sell up to an aggregate of $60.0 million of shares of its common stock. On March 9, 2018, the Company entered into a new agreement with B. Riley for the sale of up to $14.7 million of the Company’s common stock under the ATM program, pursuant to a registration statement filed on March 9, 2018 for an aggregate of $70 million of the Company’s securities, which became effective on April 16, 2018. This new ATM agreement replaced a prior sales agreement with B. Riley that expired on April 16, 2018. The ATM program amount was increased by $25.0 million in November 2018. Under the ATM program, the Company may issue and sell common stock from time to time through B. Riley acting as agent, subject to limitations imposed by the Company and subject to B. Riley’s acceptance, such as the number or dollar amount of shares registered under the registration statement to which the offering relates. B. Riley is entitled to a commission of up to 3% of the gross proceeds from the sale of common stock sold under the ATM program. During the years ended December 31, 2019 and 2018, the Company sold 1,768,012 and 7,177,755 shares of common stock under the new and expired ATM programs, respectively, and realized net proceeds of approximately $15.2 million and $22.0 million during the years ended December 31, 2019 and 2018, respectively. At December 31, 2019, the Company has approximately $4.6 million available under its current ATM program and $30.3 million available under its current shelf registration for the issuance of equity, debt or equity-linked securities unrelated to the current ATM program.
Warrants [Member]
Stockholders' Equity (Textual)
Warrants, weighted average exercise price per share					$ 7.50
Aggregate principal					$ 7,500,000
Proceeds from issuance of common stock					7,500,000
Debt discount					$ 710,000
Conversion of stock, description					The Company issued an aggregate of 1,948,207 shares of its common stock upon exercise of warrants, resulting in net proceeds of $8,674,000.
Warrants issued, description					The Company amended and restated the following warrants held by Elliott and its affiliates to reduce the exercise price of each warrant to $0.001 per share: warrants issued in May 2013 to purchase up to an aggregate of 100,000 shares of the Company's common stock with a pre-amendment exercise price of $3.25 per share and an expiration date of May 30, 2019 (the "May 30, 2019 Warrants"); and warrants issued in October 2013 to purchase up to an aggregate of 150,000 shares of common stock with a pre-amendment exercise price of $4.50 per share and an expiration date of October 22, 2019 (the "October 22, 2019 Warrants").
Exchange agreement, description					The expiration date of a warrant to purchase up to 100,000 shares of the Company’s common stock was extended from May 30, 2019 to August 16, 2019, then subsequently canceled in connection with the Exchange Agreement transaction (see Note 6). The warrant had an exercise price of $0.005. The incremental value of the warrant extended was immaterial.
Letter Agreement. description					The Company entered into Letter Agreements with Holders of Series B Warrants. Pursuant to each Letter Agreement, the Company agreed to reduce the exercise price of each Holder's Series B Warrants from $5.25 to $4.00, provided that the Holder exercised its Warrant for cash at the time of entry into such Letter Agreement. Each Holder exercised its Series B Warrants in full and the Company issued an aggregate of 1,224,263 shares of Common Stock to them. The Company received net proceeds of approximately $4,900,000. As a result of the modification of the exercise price of these warrants, the Company recognized an incremental value of $369,500.